


Pharmaceuticals & Biotechnology | Small Cap
Procter & Gamble Health Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company demonstrates strengths in solvency and efficiency, particularly in managing inventory and receivables. However, it faces significant challenges in liquidity, growth, coverage, profitability, and key financial metrics such as earnings per share and margins. Capital expenditure management appears to be a notable positive aspect. The company's overall financial health suggests a need for improvement in several areas to ensure sustainable growth and stability. While it effectively handles some operational aspects, addressing weaknesses in profitability and liquidity will be crucial for future success.
Procter & Gamble Health Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company demonstrates strengths in solvency and efficiency, particularly in managing inventory and receivables. However, it faces significant challenges in liquidity, growth, coverage, profitability, and key financial metrics such as earnings per share and margins. Capital expenditure management appears to be a notable positive aspect. The company's overall financial health suggests a need for improvement in several areas to ensure sustainable growth and stability. While it effectively handles some operational aspects, addressing weaknesses in profitability and liquidity will be crucial for future success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
30.81
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
30.81
P/B RATIO
19.20
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
7.07
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
20.58
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹6068 as on Aug 6, 2026.
The growth performance is weak across all metrics, indicating limited expansion and potential stagnation. This could stem from market saturation, competitive pressures, or ineffective growth strategies. The company may face challenges in attracting investors and maintaining market share. Focus on innovation and strategic investments is crucial to revitalize growth prospects and ensure long-term sustainability. The company needs to improve its growth prospects.
| Growth Ratios | Jun 2020 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2025 16m |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth Rate | ||||||||
| Operating Profit Growth Rate | ||||||||
| Earnings Per Share (EPS) Growth | ||||||||
| Asset Growth Rate | ||||||||
| Net Income Growth Rate |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 34.93 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 21.40 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 34.29 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 35.92 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 38.74 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 40.87 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 29.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Aarti Drugs Ltd | 7.20 | 19.23 | Undervalued | 309.00 | 18.54 | 195.00 |
| 9 | Hikal Ltd | 7.13 | -55.92 | Neutral | 220.00 | -3.95 | -49.00 |
| 10 | Shilpa Medicare Ltd | 5.94 | 59.39 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 11 | Strides Pharma Science Ltd | 5.55 | 16.53 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | Jeena Sikho Lifecare Ltd | 5.52 | 33.85 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | Orchid Pharma Ltd | 4.85 | 246.31 | Neutral | 41.00 | 8.91 | 21.00 |
| 14 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 15 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.53 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 16 | Zota Health Care Ltd | 3.97 | -58.38 | Neutral | 19.00 | 8.06 | -74.00 |
| 17 | Procter & Gamble Health Ltd | 3.45 | 30.81 | Neutral | 457.00 | 196.94 | 327.00 |
| 18 | Sanofi India Ltd | 3.45 | 18.66 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish